Compare · LH vs SPNE
LH vs SPNE
Side-by-side comparison of Labcorp Holdings Inc. (LH) and SeaSpine Holdings Corporation (SPNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LH and SPNE operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH carries a market cap of $30.23B.
- LH has hit the wire 16 times in the past 4 weeks while SPNE has been quiet.
- LH has more recent analyst coverage (25 ratings vs 5 for SPNE).
- Company
- Labcorp Holdings Inc.
- SeaSpine Holdings Corporation
- Price
- -
- -
- Market cap
- $30.23B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 5
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
SeaSpine Holdings Corporation
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Latest LH
- EVP, Pres of BLS, CMO & CSO Caveney Brian J sold $744,080 worth of shares (2,000 units at $372.04), decreasing direct ownership by 5% to 34,562 units (SEC Form 4)
- EVP and President, Diagnostics Vaughn Bryan T sold $108,232 worth of shares (306 units at $353.70) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 6,845 units (SEC Form 4)
- Labcorp Holdings Inc. upgraded by HSBC Securities with a new price target
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Speak at the UBS Global Healthcare Conference
- Director Parham Richelle P sold $389,395 worth of shares (1,078 units at $361.22), decreasing direct ownership by 32% to 2,288 units (SEC Form 4)
- EVP, CIO & CTO Oyegunwa Akinbolade converted options into 370 shares and covered exercise/tax liability with 118 shares, increasing direct ownership by 5% to 5,316 units (SEC Form 4) to satisfy tax liability
- EVP and President, Diagnostics Vaughn Bryan T converted options into 500 shares and covered exercise/tax liability with 194 shares, increasing direct ownership by 4% to 7,151 units (SEC Form 4) to cover taxes
- SEC Form 10-Q filed by Labcorp Holdings Inc.
- SEC Form 8-K filed by Labcorp Holdings Inc.
Latest SPNE
- SEC Form CT ORDER filed by SeaSpine Holdings Corporation
- SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)
- SEC Form 15-12G filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company
- SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company
- SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gaeta Renee returned 36,056 shares to the company, closing all direct ownership in the company